Developer docs
API playgroundTry for free, no card

Search company profiles

Macopharma

Full company profile

uuid000e2ad

Namestring
Macopharma
Legal namestring
Maco Pharma
Websiteurl
macopharma.com
Company typeenum
Private
Founded yearint
1977
Descriptiontext

Macopharma, founded in 1977 in northern France and headquartered in Mouvaux (Tourcoing), is a privately held medical device company operating within the GMPi (Groupe Macopharma International) holding structure. The company designs, manufactures, and distributes an integrated portfolio of blood processing solutions covering single-use disposables (blood bag systems, filtration kits, pathogen inactivation sets, transfer/pooling/sampling sets), specialized equipment (MacoPress separators, MacoSeal tube sealers, Maconnect sterile connection devices, MacoTronic illumination devices), software for traceability and process data management, and validated processing guidelines sold to blood banks, blood transfusion centers, and hospitals.

The end customers are healthcare professionals in transfusion medicine, with named reference relationships including Canadian Blood Services, Vitalant, Belgian Red Cross, and EFS France, supported by a peer-reviewed publication cadence in Vox Sanguinis and Stem Cells Translational Medicine. Macopharma's portfolio is differentiated by a series of proprietary platforms: the DEHT/PAGGSM DEHP-free blood storage system positioned ahead of the EU REACH 2030 phase-out of DEHP-plasticized blood containers, the THERAFLEX MB-Plasma and THERAFLEX UV-Platelets pathogen inactivation systems, the SSP+ platelet additive solution used in more than 40 countries, and the Maconnect multi-sterile connection device. Production is anchored in France with additional manufacturing in Tunisia and Poland and a planned Serbia factory in 2025; the company reports 15 wholly-owned subsidiaries and distribution in more than 84 countries across five continents.

Revenue was reported at €170 million for 2023, generated primarily through B2B enterprise sales via direct field sales teams and regional subsidiaries using quote-based, multi-year contract pricing. The November 2024 acquisition of German blood-industry equipment maker Lmb Technologie (€8 million 2023 revenue) is intended to roughly double equipment business sales and consolidate the value chain between disposables, equipment, and software.

Short descriptiontext

Macopharma, founded in 1977 in France, manufactures blood bag systems, pathogen inactivation technologies, sterile connection devices, separators, and processing software for blood banks and transfusion centers worldwide, generating €170 million in 2023 revenue across 84 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersTourcoing, France
HQ citystring
Tourcoing
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices17 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood processing solutions, blood bag systems, pathogen inactivation, medical disposables, blood component separation
Industry3 codes
PRIMARYHLAHAAAH
Blood Bank, Transfusion Medicine & Immunohematology
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYIMALAIAF
Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes)
SECONDARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Blood and Organ Banks621991
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Blood Processing Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Blood processing medical devices and disposables
TypeOne Time License
Description

Macopharma generates revenue primarily from the sale of single-use blood processing disposables including blood bag systems, filtration kits, pathogen inactivation sets, and transfer/pooling/sampling sets. 2023 sales of €170 million reported for Macopharma.

macopharma.com
2Blood processing equipment
TypeHardware Sales
Description

Sale of specialized equipment including MacoPress separators, MacoSeal sealers, Maconnect sterile connection devices, MacoTronic illumination machines. Lmb Technologie acquisition (2024) strengthens the equipment portfolio, targeting to double equipment business sales.

macopharma.com
3Software and data management
TypeOne Time License
Description

Software products including data management systems for traceability (Macopress Smarter), as part of integrated blood processing solutions. Lmb Technologie contributes software portfolio (agitators, separators, welders, accessories).

macopharma.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1B2B enterprise pricing via direct sales and subsidiary channels
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly disclosed. Sales are conducted through direct commercial and technical field teams across subsidiaries. Contact form on website requires country selection and product interest. Products are configured to customer specifications (volume configurations, additive solutions, filtration options).

macopharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1INNOV by Macopharma
Description

Innovation committee and process that empowers collaborators, partners and stakeholders to contribute from ideation to incubation and approval phases

macopharma.com
+6 more records
Core offering1 text field

Macopharma manufactures and sells blood processing medical devices and single-use disposables (blood bag systems, filtration kits, pathogen inactivation sets, transfer/pooling/sampling sets) along with specialized equipment (blood component separators, tube sealers, sterile connection devices, UV illumination machines) and software for traceability. The company serves blood banks, hospitals, and blood transfusion centers across 84 countries with solutions covering collection, separation, leukodepletion, pathogen inactivation, cord blood processing, and platelet preparation.

Differentiator
Functional benefit
Problem solved
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-11-22
Description

Local Serbian firm LMB Soft is partnering with Macopharma to build a new factory in Niš, Serbia. The expansion includes extending facilities and creating around 30 new high-value jobs primarily for technical university graduates by end of 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-19
Description

The international GMPi/Macopharma group acquired German company Lmb Technologie in November 2024. Lmb Technologie (founded 1979, €8m sales in 2023) is a major player in blood industry equipment including agitators, separators, welders and software. The acquisition strengthens Macopharma's equipment range, enabling coverage of the entire blood processing value chain. Synergies expected to double equipment business sales. Lmb brings exclusivity of equipment in defined geographical areas of Macopharma's 5-year strategy. Expected to complete in early 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple collaborative research studies conducted with Canadian Blood Services (Product & Process Development, Ottawa/Vancouver/Edmonton) and their NetCAD Blood4Research facility. Studies include DEHT/PAGGSM vs DEHP/SAGM RBC quality comparison, bacterial proliferation studies, and hemolysis measurement methodology. Macopharma employees co-authored published studies in Vox Sanguinis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

First US evaluation of Buffy Coat-derived platelets using whole blood processing with 24-hour hold was conducted at Vitalant Innovation Center in Denver, CO in collaboration with Macopharma. This study was critical for demonstrating the feasibility of adopting European buffy coat methods in US blood centers to maximize whole blood utilization and address platelet shortages.

5Belgian Red Cross – Service du Sang
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative multicenter study on DEHT/PAGGSM impact on RBC concentrate quality conducted with Belgian Red Cross (Service du Sang, Namur, Belgium). Joint research examining whole blood processing, storage studies up to 49 days, and quality parameter testing. Co-authors from Belgian Red Cross on peer-reviewed publication.

macopharma.com
6EFS Bourgogne Franche Comté
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborative research partner on DEHT/PAGGSM RBC quality studies, comparative SAGM vs PAGGSM studies, and process preparation impact assessments. EFS Besançon conducted whole blood processing via pool and split methods, contributing to multicenter studies with Macopharma R&D and Belgian Red Cross.

macopharma.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

INSERM (Institut national de la santé et de la recherche médicale, France) collaborated on the comparative study of SAGM vs PAGGSM storage solutions, focusing on storage-induced micro-erythrocytes and haematocrit measurement discrepancies. Contributed scientific expertise on RBC morphology research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NetCAD Blood4Research program of Canadian Blood Services collaborated on sampling pouch hemolysis measurement comparative study. Initial observation at NetCAD about expected hemolysis measurement increase when using Macopharma's sampling pouch method led to the comparative study. Study published in Vox Sanguinis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bio-Rad's clinical diagnostics division supplies blood-typing reagents and quality-control products to blood banks, directly overlapping Macopharma's transfusion-medicine customer base.

2Haemonetics Corporation
TypeDirect peer
Description

Haemonetics supplies blood and plasma component collection devices, software, and hospital-based blood-management systems. Competes directly with Macopharma's MacoPress/MacoTronic equipment, software, and consumables.

TypeBroad incumbent
Description

Octapharma is a major plasma-products manufacturer with growing activity in cell and gene therapies. Broader incumbent than Macopharma in the blood-products value chain with some overlap on the supply side of plasma used in transfusion.

TypeDirect peer
Description

Immucor specializes in transfusion and transplantation diagnostics, including reagents used in blood-bank workflows. Adjacent competitor to Macopharma for blood-center customers, with overlap in immunohematology.

TypeDirect peer
Description

Fresenius Kabi's Transfusion Medicine and Cell Technologies unit manufactures blood-collection bags, filters, separators, and storage solutions — direct overlap with Macopharma's disposable and equipment portfolio.

TypeDirect peer
Description

Grifols operates a blood-bags and disposables business alongside its plasma products franchise, competing with Macopharma in DEHP/DEHP-free blood bag systems for blood banks and transfusion centers.

7Asahi Kasei Medical
TypeDirect peer
Description

Asahi Kasei Medical produces Planova and related virus filters used in plasma and biotech processing. Competes with Macopharma's Leucoflex and blood-filtration product lines in adjacent filtration markets.

TypeDirect peer
Description

Cerus is the developer of the INTERCEPT pathogen-reduction system for platelets and plasma — a direct competing platform to Macopharma's THERAFLEX MB-Plasma and UV-Platelets systems.

TypeDirect peer
Description

Terumo BCT is the leading global supplier of blood component collection, processing, and storage systems (incl. apheresis, whole-blood processing, and pathogen reduction). Head-to-head competitor to Macopharma across blood bags, separators, and PI equipment.

TypeBroad incumbent
Description

Hologic's Diagnostic Solutions division operates blood-bank molecular screening assays (e.g., Procleix). Competes with Macopharma for blood-bank spend across adjacent diagnostic categories rather than disposables/equipment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries15 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Macopharma

Blood Processing Medical Devicesmacopharma.com

Macopharma, founded in 1977 in France, manufactures blood bag systems, pathogen inactivation technologies, sterile connection devices, separators, and processing software for blood banks and transfusion centers worldwide, generating €170 million in 2023 revenue across 84 countries.

What Macopharma does

Macopharma, founded in 1977 in northern France and headquartered in Mouvaux (Tourcoing), is a privately held medical device company operating within the GMPi (Groupe Macopharma International) holding structure. The company designs, manufactures, and distributes an integrated portfolio of blood processing solutions covering single-use disposables (blood bag systems, filtration kits, pathogen inactivation sets, transfer/pooling/sampling sets), specialized equipment (MacoPress separators, MacoSeal tube sealers, Maconnect sterile connection devices, MacoTronic illumination devices), software for traceability and process data management, and validated processing guidelines sold to blood banks, blood transfusion centers, and hospitals.

The end customers are healthcare professionals in transfusion medicine, with named reference relationships including Canadian Blood Services, Vitalant, Belgian Red Cross, and EFS France, supported by a peer-reviewed publication cadence in Vox Sanguinis and Stem Cells Translational Medicine. Macopharma's portfolio is differentiated by a series of proprietary platforms: the DEHT/PAGGSM DEHP-free blood storage system positioned ahead of the EU REACH 2030 phase-out of DEHP-plasticized blood containers, the THERAFLEX MB-Plasma and THERAFLEX UV-Platelets pathogen inactivation systems, the SSP+ platelet additive solution used in more than 40 countries, and the Maconnect multi-sterile connection device. Production is anchored in France with additional manufacturing in Tunisia and Poland and a planned Serbia factory in 2025; the company reports 15 wholly-owned subsidiaries and distribution in more than 84 countries across five continents.

Revenue was reported at €170 million for 2023, generated primarily through B2B enterprise sales via direct field sales teams and regional subsidiaries using quote-based, multi-year contract pricing. The November 2024 acquisition of German blood-industry equipment maker Lmb Technologie (€8 million 2023 revenue) is intended to roughly double equipment business sales and consolidate the value chain between disposables, equipment, and software.

Macopharma firmographics

Firmographics
Name
Macopharma
Legal name
Maco Pharma
Website
https://macopharma.com
Company type
Private
Founded year
1977
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Macopharma, founded in 1977 in France, manufactures blood bag systems, pathogen inactivation technologies, sterile connection devices, separators, and processing software for blood banks and transfusion centers worldwide, generating €170 million in 2023 revenue across 84 countries.
Ownership category
akta.pro rank

Macopharma industry classification

Industry
Product category
Blood Processing Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Blood and Organ Banks (621991)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAAAH
Blood Bank, Transfusion Medicine & Immunohematology
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYIMALAIAF
Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes)
SECONDARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Blood processing solutions
  • Blood bag systems
  • Pathogen inactivation
  • Medical disposables
  • Blood component separation

Where Macopharma is headquartered

Location

Headquarters

HQ city
Tourcoing
HQ country
France
HQ region
Europe

Offices17 records

Markets served

Macopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Blood processing medical devices and disposables: Macopharma generates revenue primarily from the sale of single-use blood processing disposables including blood bag systems, filtration kits, pathogen inactivation sets, and transfer/pooling/sampling sets. 2023 sales of €170 million reported for Macopharma.
  2. Blood processing equipment: Sale of specialized equipment including MacoPress separators, MacoSeal sealers, Maconnect sterile connection devices, MacoTronic illumination machines. Lmb Technologie acquisition (2024) strengthens the equipment portfolio, targeting to double equipment business sales.
  3. Software and data management: Software products including data management systems for traceability (Macopress Smarter), as part of integrated blood processing solutions. Lmb Technologie contributes software portfolio (agitators, separators, welders, accessories).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B enterprise pricing via direct sales and subsidiary channels

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Macopharma product offering

Product offering

Core offering

Macopharma manufactures and sells blood processing medical devices and single-use disposables (blood bag systems, filtration kits, pathogen inactivation sets, transfer/pooling/sampling sets) along with specialized equipment (blood component separators, tube sealers, sterile connection devices, UV illumination machines) and software for traceability. The company serves blood banks, hospitals, and blood transfusion centers across 84 countries with solutions covering collection, separation, leukodepletion, pathogen inactivation, cord blood processing, and platelet preparation.

Differentiator

Problem solved

Functional benefit

Brands

  • INNOV by Macopharma: Innovation committee and process that empowers collaborators, partners and stakeholders to contribute from ideation to incubation and approval phases
  • MacoSeal
  • Maconnect
  • MacoPress
  • DEHT x PAGGSM
  • THERAFLEX
  • MacoTronic

Companies that use Macopharma

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Macopharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Macopharma partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • LMB SoftminorStrategic or Co-development Partner · 22 November 2024Local Serbian firm LMB Soft is partnering with Macopharma to build a new factory in Niš, Serbia. The expansion includes extending facilities and creating around 30 new high-value jobs primarily for technical university graduates by end of 2025.
  • Lmb TechnologiecoreStrategic or Co-development Partner · 19 November 2024The international GMPi/Macopharma group acquired German company Lmb Technologie in November 2024. Lmb Technologie (founded 1979, €8m sales in 2023) is a major player in blood industry equipment including agitators, separators, welders and software. The acquisition strengthens Macopharma's equipment range, enabling coverage of the entire blood processing value chain. Synergies expected to double equipment business sales. Lmb brings exclusivity of equipment in defined geographical areas of Macopharma's 5-year strategy. Expected to complete in early 2025.
  • Canadian Blood ServicescoreStrategic or Co-development PartnerMultiple collaborative research studies conducted with Canadian Blood Services (Product & Process Development, Ottawa/Vancouver/Edmonton) and their NetCAD Blood4Research facility. Studies include DEHT/PAGGSM vs DEHP/SAGM RBC quality comparison, bacterial proliferation studies, and hemolysis measurement methodology. Macopharma employees co-authored published studies in Vox Sanguinis.
  • Vitalant Innovation CentercoreStrategic or Co-development PartnerFirst US evaluation of Buffy Coat-derived platelets using whole blood processing with 24-hour hold was conducted at Vitalant Innovation Center in Denver, CO in collaboration with Macopharma. This study was critical for demonstrating the feasibility of adopting European buffy coat methods in US blood centers to maximize whole blood utilization and address platelet shortages.
  • Belgian Red Cross – Service du SangcoreStrategic or Co-development PartnerCollaborative multicenter study on DEHT/PAGGSM impact on RBC concentrate quality conducted with Belgian Red Cross (Service du Sang, Namur, Belgium). Joint research examining whole blood processing, storage studies up to 49 days, and quality parameter testing. Co-authors from Belgian Red Cross on peer-reviewed publication.
  • EFS Bourgogne Franche ComtécoreStrategic or Co-development PartnerCollaborative research partner on DEHT/PAGGSM RBC quality studies, comparative SAGM vs PAGGSM studies, and process preparation impact assessments. EFS Besançon conducted whole blood processing via pool and split methods, contributing to multicenter studies with Macopharma R&D and Belgian Red Cross.
  • INSERMminorStrategic or Co-development PartnerINSERM (Institut national de la santé et de la recherche médicale, France) collaborated on the comparative study of SAGM vs PAGGSM storage solutions, focusing on storage-induced micro-erythrocytes and haematocrit measurement discrepancies. Contributed scientific expertise on RBC morphology research.
  • Canadian Blood Services' NetCAD Blood4ResearchcoreStrategic or Co-development PartnerNetCAD Blood4Research program of Canadian Blood Services collaborated on sampling pouch hemolysis measurement comparative study. Initial observation at NetCAD about expected hemolysis measurement increase when using Macopharma's sampling pouch method led to the comparative study. Study published in Vox Sanguinis.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Macopharma competitors and assessment

Company assessment

Direct peers

  • Bio-Rad Laboratories: Bio-Rad's clinical diagnostics division supplies blood-typing reagents and quality-control products to blood banks, directly overlapping Macopharma's transfusion-medicine customer base.
  • Haemonetics Corporation: Haemonetics supplies blood and plasma component collection devices, software, and hospital-based blood-management systems. Competes directly with Macopharma's MacoPress/MacoTronic equipment, software, and consumables.
  • Immucor: Immucor specializes in transfusion and transplantation diagnostics, including reagents used in blood-bank workflows. Adjacent competitor to Macopharma for blood-center customers, with overlap in immunohematology.
  • Fresenius Kabi: Fresenius Kabi's Transfusion Medicine and Cell Technologies unit manufactures blood-collection bags, filters, separators, and storage solutions — direct overlap with Macopharma's disposable and equipment portfolio.
  • Grifols: Grifols operates a blood-bags and disposables business alongside its plasma products franchise, competing with Macopharma in DEHP/DEHP-free blood bag systems for blood banks and transfusion centers.
  • Asahi Kasei Medical: Asahi Kasei Medical produces Planova and related virus filters used in plasma and biotech processing. Competes with Macopharma's Leucoflex and blood-filtration product lines in adjacent filtration markets.
  • Cerus Corporation: Cerus is the developer of the INTERCEPT pathogen-reduction system for platelets and plasma — a direct competing platform to Macopharma's THERAFLEX MB-Plasma and UV-Platelets systems.
  • Terumo BCT (Terumo Corporation): Terumo BCT is the leading global supplier of blood component collection, processing, and storage systems (incl. apheresis, whole-blood processing, and pathogen reduction). Head-to-head competitor to Macopharma across blood bags, separators, and PI equipment.

Broad incumbents

  • Octapharma: Octapharma is a major plasma-products manufacturer with growing activity in cell and gene therapies. Broader incumbent than Macopharma in the blood-products value chain with some overlap on the supply side of plasma used in transfusion.
  • Hologic: Hologic's Diagnostic Solutions division operates blood-bank molecular screening assays (e.g., Procleix). Competes with Macopharma for blood-bank spend across adjacent diagnostic categories rather than disposables/equipment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Macopharma social profiles

Digital presence

Macopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Macopharma leadership team

Management profile

Number of profiles

Profiles15 records

Macopharma subsidiaries and ownership

Company hierarchy

Subsidiaries15 records

Macopharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Macopharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Macopharma

What does Macopharma do?

Macopharma manufactures and sells blood processing medical devices and single-use disposables (blood bag systems, filtration kits, pathogen inactivation sets, transfer/pooling/sampling sets) along with specialized equipment (blood component separators, tube sealers, sterile connection devices, UV illumination machines) and software for traceability. The company serves blood banks, hospitals, and blood transfusion centers across 84 countries with solutions covering collection, separation, leukodepletion, pathogen inactivation, cord blood processing, and platelet preparation.

Is Macopharma a public or private company?

Macopharma is a private company. It is classified as corporate owned and is currently operating.

When was Macopharma founded?

Macopharma was founded in 1977. It employs 501 to 1,000 people.

Where is Macopharma based?

Macopharma is headquartered in Tourcoing, France, in the Europe region.

How does Macopharma make money?

Three revenue lines are on record. Blood processing medical devices and disposables are the primary driver. The others are blood processing equipment and software and data management.

Who are Macopharma's main competitors?

Direct peers on record are Bio-Rad Laboratories, Haemonetics Corporation, Immucor, Fresenius Kabi, Grifols, Asahi Kasei Medical, Cerus Corporation and Terumo BCT (Terumo Corporation). Broad incumbents are Octapharma and Hologic.

Does Macopharma have an API?

No public API is recorded for Macopharma.

What industry is Macopharma in?

Macopharma's product category is Blood Processing Medical Devices. Its primary akta.pro industry code is HLAHAAAH, Blood Bank, Transfusion Medicine & Immunohematology, with a secondary code of IMALAIAF, Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
tenderiLMB Soft and French Macopharma to build facility of 2,500 square meters in NisLMB Soft and French Macopharma will build a 2,500-square-meter facility in Nis, expanding LMB Soft's capacity. The merger aims to combine LMB Soft's blood treatment equipment with Macopharma's blood bags, creating about 30 new jobs, with construction expected to start in early 2025.SerbianmonitorFrance's Macopharma to build a factory in Niš – Serbian MonitorFrench medical device company Macopharma has merged with Niš-based firm LMB Soft and plans to expand its production facilities in Serbia by 2,500 square metres. The expansion is expected to create approximately 30 new jobs, primarily for technical engineers, with construction of the new hall anticipated to begin early next year.PR NewswireProven Clinical Efficacy of Photopheresis for a Range of Medical Conditions spells Growth in Photopheresis Products Market, TMRTransparency Market Research released a market report projecting the global photopheresis products market to grow at a 5.3% CAGR from 2019 to 2027, driven by FDA approval of extracorporeal photopheresis for cutaneous T-cell lymphoma and expanding clinical applications including organ transplant rejection and graft versus host disease. The report identifies key growth drivers such as photopheresis replacing steroid therapy due to fewer side effects, increasing corporate research initiatives, and favorable reimbursement policies, particularly in North America. Key market players include Macopharma, Haemonetics Corporation, Terumo Corporation, Med Tech Solutions GmbH, Fresenius Kabi AG, and Mallinckrodt Pharmaceuticals.PR NewswireGlobal Pathogen Reduction Systems Markets, 2015-2018, 2019-2020 - Market is Anticipated to Grow at a CAGR of Approx 20% During 2021-2025ResearchAndMarkets.com announced the addition of a global pathogen reduction systems market report to its offerings, forecasting the market to grow at approximately 20% CAGR during 2021-2025, driven by increasing prevalence of infectious diseases and rising adoption of advanced pathogen reduction technologies in blood transfusion management. The report segments the market by type, application, product, end-user, and region, with Europe currently dominating and Asia-Pacific expected to emerge as the fastest-growing region. Major companies profiled include Terumo BCT, Macopharma SA, Cerus Corporation, AngioDynamics, and Octapharma AG, as manufacturers continue adhering to higher safety protocols for pathogen reduction in blood products.PR NewswirePhotopheresis Products Market to Reach US$9.99 Billion by 2024: Government Encouragement to Expedite Growth as Demand RisesA Transparency Market Research report found that the global photopheresis products market was valued at US$223.1 million in 2015 and is projected to reach US$371.1 million by 2024, growing at a CAGR of 5.9%. The market is highly consolidated, with Macopharma, Med Tech Solutions GmbH, and Mallinckrodt collectively controlling 95% of the market, while North America held 52% of the market and Asia Pacific is expected to grow fastest at a 6.6% CAGR. Growth is driven by favorable government reimbursement policies and increasing demand for extracorporeal photopheresis therapy to treat conditions such as cutaneous T-cell lymphoma and graft-versus-host disease, though high treatment costs may limit adoption.PR NewswirePhotopheresis Products Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024A global market research report projects growth in the photopheresis products market from 2016 to 2024, driven by increasing graft versus host disease conditions and rising healthcare coverage for transplantations, though market expansion is constrained by limited treatment centers and high therapy costs averaging $8,000 per treatment in the U.S. The report identifies closed systems as the dominant product type globally, with North America leading the market in 2015 followed by Europe and Asia Pacific. Key companies profiled include Macopharma, Med Tech Solutions GmbH, Haemonetics Corporation, Fresenius Kabi AG, Terumo Corporation, and Mallinckrodt Pharmaceuticals, with the latter having acquired Therakos Inc. in 2015 to expand its hospital segment revenue.PR NewswirePhotopheresis Products Market Will Rise to US$371.1 Million by 2024: Rising Prevalence of Cutaneous T-Cell Lymphoma (CTL) to Boost Adoption, Says TMRTransparency Market Research released a market report projecting the global photopheresis products market to grow from US$223.1 million in 2015 to US$371.1 million by 2024, representing a 5.9% CAGR during the forecast period. The market is highly consolidated, with the top three players—Mallinckrodt, Macopharma, and Med Tech solutions GmbH—accounting for over 95% of the market in 2015, while North America held the largest regional share at over 52%. Rising prevalence of cutaneous T-cell lymphoma and favorable government reimbursement policies are identified as key growth drivers, though high treatment costs averaging US$8,000 per session and lengthy treatment durations may restrain market expansion.